Autoimmune Treatment

By Author: Bharat book
Total Articles: 1486
Comment this article

Autoimmune Treatment (2009 - 2014) report  ( http://www.bharatbook.com/Market-Research-Reports/Autoimmune-Treatment.html ) analyzes the submarkets for applications, products, services, and technologies. The global market for autoimmune disease treatments is estimated to be at $37.84 billion in 2009, and is growing at a CAGR of 12.7% from 2009 to 2014 to reach an estimated $68.81 billion in 2014. The effects of the global meltdown are given careful consideration when forecasting the market.
Autoimmune disorders result from an overactive immune response of a body working against its own cells. The disease is broadly classified into two types: systemic autoimmune diseases, which affect several organs of the body; and localized autoimmune diseases, which affect only one organ. Around 80 autoimmune diseases are recognized under these two categories. The disease affected over 300 million people across the globe in 2009. No defined reasons have been discovered to date for the occurrence of the disorder. Women are more prone to autoimmune diseases, constituting 70%-75% of all autoimmune patients.
The application market ...
... is further classified into the treatment markets for systemic autoimmune diseases and localized autoimmune diseases. The applications market is dominated mostly by rheumatoid arthritis under the systemic disease segment, while multiple sclerosis is the major application market under the localized disease segment. These two disorders account for 75% of the total applications market. The other major diseases analysed under the application market are psoriasis, lupus, type I diabetes, inflammatory bowel disease, and thyroid disorders, which together account for 15%-20% of the global applications market.

The product market is classified on the basis of the drugs, diagnostic equipments, therapeutic and monitoring equipment. Drugs form the largest segment of the products market, with major drugs such as NSAID, DMARD, biologic DMARD, Avonex, Rebif, Copaxone, Betaseron, and 5-ASA. The services market consists of consultation and diagnosis, therapy and monitoring, and drug development. The wide and increasing prevalence of autoimmune diseases is boosting the drugs market along with the therapy and monitoring market; along with the fact that almost all autoimmune diseases are chronic and have no permanent cure.

The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014.
Key questions answered

Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, stakeholders?
What are market estimates and forecasts; which markets are doing well and which are not?
Where are the gaps and opportunities; what is driving the market?
Which are the key playing fields? Which are the winning edge imperatives?
How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

To know more and to buy a copy of your report feel free to visit :http://www.bharatbook.com/Market-Research-Reports/Autoimmune-Treatment.html
Or

Contact us at :
 
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: press@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook